Despite much progress, the functions of the majority of viral miRNAs remain unknown. Most previous studies have used biochemical methods to uncover targets of viral miRNAs, but it is unclear what fraction of these targets is functionally important. Here, we apply an alternative strategy based on the premise that assorted viral miRNAs will share functionality. Screening a library of >70 human viral miRNAs showed that three unrelated miRNAs from distantly related herpesviruses significantly inhibited IFN signaling. Strikingly, each of these miRNAs directly reduced expression of the cyclic AMP-responsive element-binding protein (CBP), which as part of the p300-CBP complex, mediates IFN signaling. We show that both 5′ and 3′ derivatives from Epstein-Barr virus (EBV) encoded miR-BART-18 precursor miRNA (pre-miRNA) and the orthologous pre-miRNA from Rhesus lymphocryptovirus contribute to reducing IFN signaling. Thus, through both convergent and divergent evolutionary mechanisms, varied herpesviral miRNAs share the ability to decrease IFN signaling. Restoring miR-BART-18 to cells infected with an EBV miRNA mutant conveyed a cellular growth advantage upon IFN treatment, and relevant miRNAs from other herpesviruses were able to complement this activity. Blocking miR-BART-18 function in an EBV + tumor cell line renders cells more susceptible to IFN-mediated effects. These findings provide a mechanism that can at least partially explain the resistance of some EBVassociated tumors to IFN therapy. Our work suggests that similar pan-viral-miRNA functional-based screening strategies are warranted for determining relevant activities of other viral miRNAs.
M icroRNAs (miRNAs) are a class of small regulatory RNAs that have attracted much attention as regulators of diverse biological activities. Both host and viral miRNAs have been implicated in the control of processes relevant to virus infection, including the immune response, cell death, and regulation of virus gene expression (1) (2) (3) (4) (5) . Viral miRNAs have generated excitement, in part, as a previously unrecognized class of gene products that could contribute to understanding the mechanisms of viral disease. Biochemical cross-linking studies have identified direct transcript targets of miRNAs and have provided much insight into viral miRNA biology (6) (7) (8) (9) . However, there remain many unanswered important questions. For example, there is little understanding of how viral miRNA genes evolve and the functions of the majority of miRNAs remain unknown. Like host miRNAs, individual viral miRNAs can bind to numerous targets, but is unclear what fraction of these targets are biologically meaningful (1, 10) .
The majority of viral miRNAs are found in viruses that take up long-term persistent infections (11) . In particular, most reported viral miRNAs are encoded by herpesviruses (1, 4, (11) (12) (13) . Infection with herpesviruses is associated with serious disease, including several different cancers. Epstein-Barr virus (EBV), the most common herpesviral human tumor virus, is associated with lymphocyte and solid tissue cancers (14) . Like most herpesviruses studied, EBV encodes numerous-at least 25-pre-miRNAs that give rise to even more bioactive derivatives (15) (16) (17) (18) . EBV tumors mostly undergo latent infection, a state of limited viral gene expression without virus production. In some latent states, noncoding RNAs are the only abundant viral gene products expressed (19) (20) (21) (22) . Independent studies implicate oncogenic activity of viral miRNAs in at least some EBV-associated tumors (13, (23) (24) (25) (26) . Developing more effective therapies against EBV-associated tumors could save thousands of lives each year (27) . Recently, adaptive immune response-based therapies have shown much promise (28) (29) (30) . In contrast, innate immune therapies based on treatment with type I IFNs have shown limited success (31) (32) (33) . Positive responses have only been observed in a subset of patients and tumor types (30, 33) . Deciphering the functions of EBV miRNAs has utility not only in understanding EBV biology and disease but potentially also tumor response to treatment. In this study, we use a functional-based screen of all known human herpesviral miRNAs, and additional human viral miRNAs, to uncover an EBV miRNA that inhibits IFN signaling and associated growth arrest. This activity is shared with miRNAs from closely related and distantly related herpesviruses, and our work indicates that this shared activity occurs at least in part through a common host target. These findings expand the understanding of viral miRNA function and herpesvirus latency, and may help explain the response of tumors to IFN therapy.
Results
Functional Screen Identifies Inhibition of IFN Activity by Herpesviral miRNAs. miRNA target identification strategies have led to much insight into viral miRNA function, but it remains unclear how comprehensive these approaches are, and what fractions of the identified targets are virologically relevant. To complement these approaches, we undertook a "functions-first" study based on the premise that similar to regulatory viral proteins, miRNAs from
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As part of the host-pathogen evolutionary arms race, viruses must develop mechanisms to evade host defenses. Viral miRNAs, small regulatory RNAs, are likely key weapons in this struggle. Most previous studies attempted to understand viral miRNA functionality starting with target identification. Here, we use an alternative "functions-first" approach to test the hypothesis that miRNAs from distantly related viruses share common functions. Our work identifies evasion of the antiviral cytokine interferon as a common activity of divergent herpesviral miRNAs. This approach expands our understanding of latent infection and may at least partly explain the resistance of some herpesviralassociated tumors to interferon-mediated therapy. This work demonstrates the utility of functional-based screening for uncovering relevant viral miRNA activities. different viruses will possess shared functionality. We constructed a miRNA expression library expressing 70 high-confidence human miRNAs from the polyomavirus, anellovirus, and herpesvirus families, plus an additional 27 constructs for less-confident human viral miRNAs and viruses that only rarely infect humans (Table S1 ). We tested a subset of 30 of these constructs and confirmed via Northern blot analysis that transfection of our vectors gave rise to physiological miRNA levels (Fig. S1) . We chose to screen for miRNA-mediated inhibition of IFN as a potential widespread activity of viruses for two reasons: (i) proteins that hinder the IFN response are nearly universal among mammalian viruses, and (ii) we have already demonstrated that the unrelated viruses, Torque teno virus tth8 (TTV-tth8) and Simian Foamy virus of African green monkey (SFVagm) encode miRNAs that inhibit type I IFN signaling (34, 35) . Thus, we conducted a screen to identify those human viral miRNAs that block IFNmediated signaling.
HEK293T cells were cotransfected with an IFN-responsive luciferase reporter and individual members of our viral miRNA library, or a positive control vector expressing miR-132. Fortyeight hours posttransfection, IFN was added for 14 h and then a luciferase assay was conducted (Fig. 1A) . As expected, miR-132, which has previously been shown to inhibit IFN signaling (35, 36 ) scored in our assay by reducing the IFN-induced transcription of the firefly-Luc reporter by 35%. Additionally, three herpesviral miRNAs consistently scored as having a ≥25% reduction (Fig. 1B) . These miRNAs were EBV miR-BART-18, Kaposi's sarcoma-associated herpesvirus (KSHV) miR-K12, and human cytomegalovirus (HCMV) miR-US25-2. Subsequent analysis centered on these three herpesviral miRNAs.
Herpesvirus miRNAs Inhibit IFN-Induced Growth Arrest. We have previously shown that a lymphoblastoid cell line (LCL), GM19240, immortalized with EBV strain B95.8, undergoes growth inhibition upon treatment with type I IFN at levels comparable to reported therapeutic dosages (32) (33) (34) (35) . As B95.8 is a deletion mutant virus lacking 20 of the 25 pre-miRNAs (including miR-BART-18) ( Fig.  2A ) (37) , we asked if restoring miR-BART-18 expression to GM19240 cells increased cell growth in the presence of IFN. Similar to the positive control miR-132, miR-BART-18 partially hindered the growth inhibitory effects of IFN treatment (Fig. 2B) . Therefore, miR-BART-18 can reduce IFN signaling activity in the context of EBV latent infection. Next we asked whether miRs K12 and US25-2 could functionally complement miR-BART-18 in promoting cellular growth in the presence of IFN. Indeed, both of these miRNAs were sufficient to enhance growth of GM19240 cells upon IFN treatment (Fig. 2B ), albeit to a lesser degree than miR-BART-18. To further elucidate the mechanism by which miR-BART-18 provides a growth advantage, LCLs grown in the presence of IFN were assayed for cell viability and alterations in cell cycle rate. miR-BART-18 expression provided no measurable protection from IFN-mediated cell death compared with irrelevant miRNA or control empty vector (Fig. S2A ). However, cell proliferation analysis demonstrated that upon IFN treatment, miR-BART-18-expressing LCLs divide at a faster rate than cells expressing either an irrelevant miRNA or a control vector (Fig. 2C and Fig. S2B ). Taken together, these results demonstrate that diverse human herpesviruses encode miRNAs that inhibit IFNmediated signaling, and this has the functional consequence of conditionally promoting cell growth in latently infected cells.
CBP Is a Direct Target of Herpesviral miRNAs. To identify targets that could account for the IFN inhibitory effects of miR-BART-18, we integrated previously published immunoprecipitation (7, 38) and mRNA steady-state level microarray studies (39, 40) , and asked which putative targets overlapped between the studies. Then, using DAVID analysis (41), we determined which of these overlapping candidate targets were functionally implicated in the antiviral response (Fig. 3A) . This analysis identified five putative miR-BART-18 target transcripts (Fig. S3A) . To determine which of these putative targets are directly regulated by miR-BART-18, we generated and screened 3′UTR luciferase reporters for regulation by miR-BART-18. Of the five putative targets, only the cyclic AMP-responsive element binding protein (CBP) 3′UTR reporter was significantly down-regulated by cotransfection of plasmid-expressing miR-BART-18 (Fig. S3B) . To determine if this regulation was direct, we generated a reporter with two nucleotides mutated in the putative miR-BART-18 5p docking site. These mutations abolished regulation, thereby confirming that miR-BART-18 directly regulates CBP transcripts (Fig. 3C) . Next, we examined the effect of miR-BART-18 expression on endogenous CBP protein levels. HEK293T cells were transfected with a vector expressing miR-BART-18 and total protein was harvested. Immunoblot analysis showed that expression of miR-BART-18 decreased CBP protein levels relative to actin (Fig.  3D) . Unlike typical pre-miRNAs, pre-miR-BART-18 has been reported to give rise to both abundant 5′ (5p) and 3′ derivate (3p) miRNAs, depending on cellular context (39, 42, 43) . We confirmed that expression of pre-miR-BART-18 gives rise to approximately equally abundant 5p and 3p derivatives in HEK293T cells (Fig. S4B) . To determine if both the 5p and 3p miRNAs can regulate CBP transcripts, or alternatively, whether miR-BART-18 5p exclusively regulates CBP levels, we used specific molecular sponges against either the 5p or 3p miR-BART-18 miRNAs. Each sponge was confirmed to specifically inhibit 5p or 3p miRNA activity via luciferase assay performed on 5p-or 3p-specific luciferase reporters (Fig. S5A) . We further demonstrated that the sponges were effective, because the mean fluorescent intensity of eGFP, whose expression derives from the coding portion of the sponge transcripts (44, 45) , is lower only in cells that express miR-BART-18 (Fig. S5B) . Cotransfection of the individual sponge vectors with a miR-BART-18 expression vector indicated that CBP protein levels are partially restored only in the presence of the 5p sponge (Fig. 3E) . Combined, these results demonstrate that miR-BART-18 5p directly inhibits CBP expression.
Because miRs BART-18, K12, and US25-2 scored to a similar degree in both the IFN signaling and growth promotion assays, we interrogated whether there are any putative miRNA binding sites in the CBP transcript for miRs K12 and US25-2. In fact, bioinformatic analysis identified nonoverlapping complementary regions in the 3′UTR of CBP to the seed regions of both miRs K12 and US25-2 (Fig. 3B) . As seed regions are established as playing a particularly important role in mediating direct interaction between the miRNA and target, we generated luciferase reporters with either the WT 3′UTR of CBP or identical versions except with the candidate miRNA seed docking sites mutated. Cotransfection of vectors expressing either miR-K12 or miR-US25-2 with WT CBP 3′UTR reporters resulted in down-regulation of luciferase levels, and this was ablated when the respective putative miRNA docking sites were mutated (Fig. 3C ). These data suggest that miRs K12 and US25-2 directly regulate CBP transcripts. To determine if these miRNAs could alter endogenous CBP protein levels, we transfected cells with vectors expressing either miR-K12 or miR-US25-2 and then immunoblotted for CBP levels. In contrast to the empty vector-transfected control cells, both miRs K12 and US25-2 reduced endogenous CBP protein levels (Fig. 3D ). These data demonstrate that like miR-BART-18, miRs K12 and US25-2 directly regulate CBP levels.
Both miR-BART-18 5p and 3p Contribute to IFN Signaling Repression.
Our observation that unrelated miRNAs down-regulate CBP and IFN-mediated signaling implies that different human herpesviruses have converged on this strategy as a common way to evade a host defense. Given the presumed importance of such regulation, one prediction from these findings is that closely related viruses should also display similar regulatory activities.
To test this, we screened pre-miR-24 from Rhesus lymphocryptovirus (rLCV), which is orthologous to the premiR-BART-18 locus (Fig. S4A) (16, 46) . Indeed, rLCV-miR-24 inhibited IFN-mediated signaling to a similar degree as miR-BART-18 ( Fig. 4B) . Our above work (Fig. 3) established a role for miR-BART-18 5p in directly regulating CBP, but it does not rule out contributions of the 3p derivative in evading IFN-mediated signaling via other targets. To test this possibility, we used our sponges that target either the miR-BART-18 5p or 3p miRNAs (Fig. S5A) . As expected, cotransfection of the 5p sponge with the miR-BART-18 expression vector substantially restored luciferase levels in the IFN-mediated signaling assays. The 3p sponge did not restore reporter levels to the same degree as the 5p sponge, but significant activity was still observed (Fig. 4A) . Combining both sponges resulted in restoration of almost 100% of the luciferase activity, thereby suppressing nearly all IFN-inhibitory activity of the pre-miR-BART-18 (Fig. 4A) . These results suggest that although the 5p derivative accounts for the majority of IFN inhibitory activity of pre-miR-BART-18, there is also an additional smaller contribution from the 3p miRNA. Based on our above studies (Fig. 3E ), the target of the 3p miRNA is unlikely to be CBP, thereby implicating additional target transcripts in the IFN suppressive activity of miR-BART-18. To our knowledge, this makes pre-miR-BART-18 one of the few pre-miRNAs to have documented identical bioactivity from both the 5p and 3p derivatives. We performed similar sponge studies on rLCV miR-24 and observed the same trend, suggesting that this atypical feature of pre-miR-BART-18 is evolutionarily conserved (Fig. 4B) . Thus, both closely related and more distantly related herpesviruses express IFN-inhibitory miRNAs.
Our above studies suggest that targeting CBP accounts for the major IFN inhibitory effects of miR-BART-18, with smaller additive contributions from additional targets. To better define the potential magnitude of the contribution of targeting CBP, two different experiments were performed. First, we combined knockdown of CBP with BART-18 expression. We treated cells with an siRNA specific for CBP transcripts and this resulted in specific knockdown of CBP proteins levels (Fig. 4C ). When cells with reduced CBP levels were treated with IFN, a significant reduction in IFN signaling was observed (Fig. 4C) . However, coexpression of miR-BART-18 and the CBP siRNA did not result in an enhanced inhibition of IFN signaling. Second, we coexpressed miR-BART-18 and a version of CBP that is resistant to miR-BART-18 5p regulation. Cotransfection of a CBP expression construct (lacking its natural 3′UTR and associated miR-BART-18 docking site) with the miR-BART-18 expression vector resulted in near full restoration of interferon-stimulated response element (ISRE) activity (Fig. 4D) . Combined, these results show that although other targets contribute, repressing CBP transcripts accounts for a large fraction of the IFN-inhibitory activity associated with miR-BART-18.
BART-18 Reduces IFN-Mediated Effects in an EBV
+ Tumor Cell Line.
Although we confirmed physiologically relevant levels of miR-BART-18 in the above studies, we wished to determine whether miR-BART-18 expressed from the EBV genome can inhibit IFN activity. Akata A.15 cells are a Burkitt's lymphoma cell line latently infected with EBV (47, 48) . Consistent with previous studies (40, 49), we were able to confirm that Akata A.15 cells express miR-BART-18 5p (Fig. 5A ). We transduced Akata A.15 cells with a vector containing both sponges against miR-BART-18 5p and 3p, and selected for cells expressing the construct. The sponges were active in these cells because immunoblot analysis showed increased CBP levels compared with cells transduced with control sponge constructs ( previous studies relied on miRNA target identification as the starting point for uncovering viral miRNA functions. In contrast, we used a "functions-first" approach and uncover that distantly related human herpesviruses encode miRNAs that suppress the IFN response. We integrated these findings with previously reported candidate viral miRNA target datasets and show that CBP is a common target of herpesviral miRNAs, and that targeting CBP allows for suppression of IFN-mediated signaling.
The fact that distantly related viruses encode miRNAs of unrelated sequence that score for the same activity implies that these viruses have converged on the same strategy to combat a host defense. The fact that EBV and the closely related rLCV both encode sequence-related pre-miRNAs that give rise to two different miRNAs with the same functionality, implies that these pre-miRNAs diverged from a common ancestor that also shared these atypical features. Thus, through both convergent and divergent evolutionary mechanisms, herpesviruses regulate CBP and the IFN response. Although reducing CBP levels clearly can reduce IFN activity, it remains likely that additional miRNA targets contribute. In particular, the fact that both the 5p and 3p derivatives of miR-BART-18 and rLCV-miR-24 contribute to IFN inhibition implies additional host targets contribute to suppression of IFN activity. Nevertheless, coexpression of anti-CBP siRNAs and miR-BART-18 did not result in additional suppression of IFN activity and restoring CBP expression in miR-BART-18-expressing cells recovered most of the IFN-responsive activity in these cells (Fig. 4C) . These findings suggest that targeting CBP accounts for the majority of IFN suppressive activity of miR-BART-18, or that CBP activity is downstream of any additional relevant targets. In addition to promoting IFN-mediated signaling, it is well established that CBP also participates in transactivation of type I IFN. Thus, targeting CBP may help herpesviruses evade both the induction and effector phases of the IFN response. Conversely, herpesviral miRNA-targeting of CBP could have benefits to these viruses in addition to evading the antiviral IFN response. For example, recruitment of active CBP/p300 promotes lytic activation of herpes simplex virus-1 (51). Thus, miRNA-mediated suppression of CBP may promote latency by restricting lytic activation. In support of this notion, it is interesting that both miRs BART-18 and US25-2 have been implicated in promoting latent infection (40, 52, 53) . Thus, viral miRNA regulation of CBP could represent a multipronged approach to enhancing viral fitness.
Combined with previous publications showing that a retroviral and an annelloviral miRNA block IFN activity (34, 35) , our current work demonstrates that miRNA-mediated IFN inhibition is a common activity that is shared among related and disparate viruses. Because inhibition of the IFN response has been linked with cancer (54), our findings suggest that these viral miRNAs could contribute to maintenance of tumors associated with EBV and KSHV. In addition to any direct role in cancer, our observation that miR-BART-18 inhibits IFN signaling, and the associated cell growth arrest, may partly account for the resistance of some EBV-associated tumors to IFN treatment in the clinic. Finally, our work further emphasizes the utility of functional-based assays for uncovering relevant viral miRNA activities and targets. IFN Signaling Assay. Viral miRNA expression vectors were cotransfected with an IFN response reporter into HEK293T cells. Cells were treated with 10 μ universal IFN and after 14 h a dual-luciferase assay was performed. Induction of the IFN response is shown relative to an empty-vector control. miR-BART-18 or control sponges were cotransfected in indicated experiments. ffLuc values were normalized to rLuc to control for transfection efficiencies. Induction of IFN signaling is shown relative to empty vector. Further details have been previously described (34, 35) . Cell Division Assay. LCLs expressing miR-BART-18 or controls were treated with carboxyfluorescein diacetate succinimidyl ester (CFSE), a dye that decreases with each cellular division. FACS analysis was performed to determine the number of divisions in cells treated with 750 μ of daily IFN or a BSA control.
MicroRNA Target Reporter Assay. Luciferase-based reporter constructs were cotransfected with miRNA expression vectors or empty-vector controls into HEK293T cells. After 24 h, a dual-luciferase assay was performed. Luciferase values are normalized relative to empty-vector control.
ISG Induction. Akata A.15 cells expressing miR-BART-18 or control sponges were treated with 100 μ universal IFN. RNA was harvested at several time points posttreatment and resolved using a formaldehyde gel. ISG-15 and actin probes were radioactively labeled. All primers and oligos are listed in Table S2 .
Western Blot Analysis. Western blot analysis was performed as previously described (34) .
Small RNA Northern Blot Analysis. Small RNA Northern blot analysis was performed as previously described (18) . Plasmids. Viral miRNAs used in the IFN signaling screen were amplified from genomic DNA prepped from virally infected cells with the exception of hCMV. hCMV miRNAs were amplified from genomic DNA cloned into a BAC. Positive control hsa-miR-132 was amplified from custom oligos (Integrated DNA Technologies). The amplicons were cloned into pENTR/D using BP clonase enzyme mixture (Life Technologies). miRNAs were transferred into modified pLenti CMV/TO GFP-Zeo DEST vector (Addgene 17431) (1) using LR clonase enzyme mixture (Life Technologies). To drive the expression of viral miRNAs, the CMV/TO promoter was excised using ClaI and SpeI sites and replaced with an EF1α promoter excised from pcDEF3. EBV-BART-18, rLCV-miR-24, KSHV-K12-12, and CMV-US-25-2 pre-miRNAs were generated by annealing overlapping oligos (Integrated DNA Technology). The nonoverlapping portion of the oligos were filled in using Phusion high-fidelity DNA polymerase (New England Biolabs) and subsequently cloned into the XhoI/XbaI sites of pcDNA3.1-puro. Overlapping oligos (Integrated DNA Technology) for WT or control molecular sponges were annealed and subsequently filled in using Phusion high-fidelity DNA polymerase (New England Biolabs) and cloned into the 3′UTR of pcDNA3.1-eGFP using XhoI and XbaI sites. Luciferase reporters of partial 3′UTRs (∼700-1,000 nt) were constructed by amplifying human genomic DNA isolated from HEK293T cells using a genomic DNA isolation kit (QiAamp DNA mini Kit, Qiagen) using standard PCR. The amplicon was cloned into the XhoI /XbaI sites of a pcDNA3.1dsRluc vector. Three separate reporters for the 3′UTR of CBP (500 nt each) containing the predicted miRNA docking site of miR-BART-18, miR-K12, and miR-US25-2 were amplified from custom oligos (g-blocks; Integrated DNA Technology) and cloned into the XhoI /XbaI sites of the pcDNA3.1dsRluc vector. Seed mutant reporters were amplified from custom oligos that contained 2-nt changes within each miRNA predicted seed region. All primers and oligos are listed in Table S2 . All constructs were confirmed by Sanger sequence analysis through the Institute of Cellular and Molecular Biology sequencing Facility at the University of Texas at Austin.
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Lentivirus Production. Herpesvirus miRNAs, miR-132, and molecular sponges were subcloned into pLB2 CAG P2Gm (Addgene #19752) (2) lentivector using NotI and PmeI sites. The following plasmids were transfected into a 10-cm 2 plate of HEK293T cells: 11.7 μg miR expression vector, 3.5 μg pMD2.G (Addgene #12259) (3), 2.9 μg pRSV-Rev (Addgene #12253) (3), and 5.9 μg pMDLg/pRRE (Addgene #12251) (3) using Lipofectamine 2000 (Invitrogen). Viral particles were harvested at 24 and 48 h posttransfection and subjected to a 0.2-μm filter (VWR). Next, 20 μL of serial dilutions of viral stocks were added in triplicate to 24-well plate of 10 5 HEK293T cells along with 1.5 μL polybrene (Sigma-Aldrich) (10 μg/mL). After 48 h, the cells were washed with PBS and visually assessed for percent GFP + using fluorescent microscopy. Cell titers were calculated using the following equation: [(percent positive GFP × number of cells)/100× volume of viral dilution added to each well)] × 1/dilution factor (4). Titers represent transducing units (TU) per milliliter.
Generation of Stable Cell Lines. One milliliter of miRNA or empty vector lentiviruses (1 × 10 6 TU) was added to a six-well of 5 × 10 5 GM19240 B-cells using 5 μL polybrene (10 μg/mL). Next, 1.5 mL of molecular sponge expressing lentiviruses (5 × 10 5 TU) was added to a six-well of 1 × 10 5 Akata A.2, A.15 or GM19240 cells lines using 5 μL polybrene (10 μg/mL). All transductions were done in duplicate and included a polybrene only control. After 24 h, cells were pelleted to remove traces of polybrene and resuspended in fresh media. All stable cell lines were selected every 3 d with 2 μg/mL puromycin for 2 wk then pooled. The polybrene only control did not survive the first week of selection. (8), levels reflective of some natural conditions. An empty-vector control was treated with both IFN and BSA (50 ng). A dual-luciferase assay was performed 14 h post-IFN treatment. ffLuc (ISRE reporter) was normalized to rLuc to control for differences in transfection efficiency. Induction of the reporter was calculated by dividing normalized levels of IFN treated empty vector with BSA treated empty vector. The induction of IFN signaling was calculated for each miRNA expression vector relative to empty vector. Except where noted, three independent experiments of triplicates were performed. A Student's t test was used to determine significance.
Growth Assay of IFN-Treated Cells. For the growth assay of IFNtreated cells, 2.5 × 10 6 herpesviral miRNA, control miRNA, empty vector or molecular sponge GM19240 stable cells were treated daily with 750 units IFN (in 2-mL total volume) or 1 μg BSA in triplicate for 5 d. Next, 5 × 10 5 control or miR-BART-18 sponge Akata A.15 cells were treated with 750 units IFN (in 2-mL total volume) for 7 d. We used the following independent rationales to compare our experimental conditions to therapeutic settings. Patients are often treated with 5-20 million units IFN per square meter of body surface area (9) (10) (11) . A six-well plate has a surface area of 962 mm 2 , therefore our treatment corresponds to roughly 1 million units IFN/m 2 . Separately, the average human has a volume of 65 L (6.5 × 10 4 mL) and is treated with 20-30 × 10 6 units of IFN (or even higher). Thus, IFN treatment for patients can be ∼500 U/mL (the experimental conditions we used are 325 U/mL). Together, two independent rationales support that our IFN treatments fall within some therapeutic conditions applied to humans in vivo. Viable cell count for the GM19240 cell lines and Akata A.15 cell lines were calculated daily using exclusion of Trypan blue staining and a hemocytometer. Percent viability was calculated for spongeexpressing GM19240 cells by dividing Trypan blue negative cells by the total number of cells. The experiment included three biological replicates with three technical replicates for each experiment. A Student's t test was used to determine significance.
Cell Division Assay of IFN-Treated Cells. GM19240 cells stably expressing herpesviral miRNA, control miRNA, or empty vector were incubated with 10 μM CellTrace CFSE reagent for 20 min at 37°C and subsequently washed with RPMI. Next, 2.5 × 10 6 cells were seeded into a six-well plate and treated daily with 750 units IFN or 1 μg BSA in triplicate for 5 d. Fluorescent intensity was analyzed after 5 d using a BD LSRII Fortessa flow cytometer. The data were analyzed using the proliferation platform on FlowJo v8. The experiment was independently repeated twice with three replicates per each experiment.
Luciferase Reporter Assay. For the luciferase reporter assay, 2 × 10 5 HEK293T cells were seeded into a 24-well plate. Wells were transfected with 5 ng rLuc-reporter, 5 ng ffLuc, and 500 ng pcDNA3.1 miRNA expression vector or empty vector using 3 μL Lipofectamine 2000. Next, 1 μg pcDNA3.1-eGFP-sponge was included in indicated experiments. After 24 h, a dual-luciferase assay was performed according to the manufacturer's protocol (Promega). rLuc values were normalized to ffLuc to control for differences in transfection efficiencies. Results of the luciferase assay are shown relative to empty vector. Three biological replicates preformed in triplicate were conducted. A Student's t test was used to determine significance.
Western Blot Analysis. In a six-well plate, 4 μg of pcDNA3.1 miRNA expression plasmid, 4 μg empty vector, pcDNA3β-FLAG-CBP-HA expression vector (Addgene #32908) (5), or 100 pmol of siRNA was transfected with Lipofectamine 2000 into 1 × 10 6 HEK293T cells. After 48 h, protein was harvested in 200 μL RIPA buffer (0.1% SDS, 1% Triton X-100, 1% deoxycholate, 5 mM EDTA, 150 mM NaCl, and 10 mM Tris at pH 7.2) that included Complete Mini Protease Inhibitor tablets (Roche). Next, 1 × 10 6 Akata A.15 cells expressing sponge constructs were pelleted and resuspended in 100 μL RIPA buffer. Fifty micrograms of total protein was separated on a 6% SDS-polyacrylamide gel and transferred to a nitrocellulose membrane (Bio-Rad). Membranes were blocked with 5% (wt/vol) milk in 1% TBST (0.1% Tween 20, 1× Tris-buffered saline) at 4°C overnight. Primary antibodies used were CBP (F-12): sc-365915, β-actin (C-4): sc-47778 (Santa Cruz Biotechnology), and anti-flag (M1): F3040 (Sigma-Aldrich). Blots were probed with a 1:500 dilution CBP antibody and 1:1,000 dilution of β-actin antibody in 5% milk in 1% TBST. IRDye 680LT secondary antibodies (LI-COR) were diluted 1:10,000 in 5% milk in 1% TBST. Blots were washed four times with TBST between addition of primary and secondary antibodies. Blots were scanned using Odyssey CLx infrared imaging system (LI-COR). Band intensities were measured with Image Studio software (LI-COR). The experiment was repeated three independent times. A Student's t test was used to determine significance.
Small RNA Northern Blot Analysis. For small RNA Northern blot analysis, 1 × 10 6 HEK293T cells in a six-well plate were transfected with either 4 μg pcDNA3.1 miRNA expression vector or 250 ng pLenti CMV/TO GFP-Zeo DEST vectors using 10 μL or 2.5 μL Lipofecatmine 2000, respectively. Forty-eight hours posttransfection, RNA was harvested using a homemade PIG-B solution [2 M guanidinium thiocyanate (EMD), 20 mM citrate buffer, pH 4.5, 5 mM EDTA (Fisher Scientific), 0.25% Sarkosyl (Sigma Aldrich), 48% (vol/vol) saturated phenol, pH 4.5 (Amresco), 2.1% isoamyl alcohol (Fisher Scientific), 0.5% β-mercaptoethanol (Sigma Aldrich), 0.1% 8-hydroxyquinoline (EMD), and 0.0025% Coomassie blue (EMD)]. Next, 1 × 10 6 Akata A.2 and A.15 cells were pelleted and resuspended in PIG-B for RNA harvest. Ten micrograms total RNA was separated on a Tris-borate-EDTA-Urea-15% polyacrylamide gel and transferred onto an Amersham Hybond N+ membrane (GE Healthcare). Probing reactions were performed as previously described (12) . Probes are listed in Table S2 . Akata A.15 cells expressing miR-BART-18 sponge or control sponge were treated with 100 units IFN. RNA was harvested at 0, 6, 12, 24, and 48 h posttreatment using PIG-B, as described above. Ten micrograms of total RNA was separated in a 1.2% agarose, 2.2 M formaldehyde gel. RNA was transferred to an Amersham Hybond N+ membrane using capillary action. Fulllength ISG-15 cDNA digested from an ISG-15 expression vector (13) was labeled with 32 P using random prime (Rediprime II, Random Prime Labeling System; GE Healthcare). Hybridization took place overnight at 60°C in Express Hybridization buffer (Fisher Scientific). The membrane was exposed to a phososcreen and processed with a phosphoimager. Blots were stripped and reprobed for actin. Actin was amplified from genomic DNA extracted from HEK293T cells and radioactively labeled using random prime. Details of actin probing have been previously described (14) .
Bioinformatics Analysis. Data from four studies were analyzed using the following criteria: (i) direct cross-linking of miR-BART-18 to an mRNA (15); (ii) enrichment of mRNA in Ago2 pull-downs (16); and (iii) decrease in steady-state levels of mRNAs (17, 18) . The UTRs of mRNAs that were identified in more than three studies were retrieved from Ensembl (19) and those with predicted miR-BART-18 docking sites were passed through DAVID analysis (20, 21) . Genes were classified into functional groups using low stringency. Genes falling into the IFN-α/β classification were considered for further analysis. Data from four studies, two that relied on miRNA:mRNA association with RISC and two that relied on changes in mRNA steady-state levels in the presence of specific miRNAs, were integrated to identify miR-BART-18 targets (7) (8) (9) (10) . Targets that were found in ≥3 of the studies underwent DAVID analysis to identify transcripts involved in the IFN response. Five high-confidence targets were identified. (B) Reporter constructs containing 3′UTRs of candidate miR-BART-18 targets were cotransfected with miR-BART-18 expression vector, irrelevant miRNA expression vector (miR-SV40), or mock-empty vector, and then a dual-luciferase miRNA activity assay was performed. Luciferase values were normalized to empty vector control. Error bars represent SEM of three independent experiments performed in triplicate. Table S1 . miRNA regulation of IFN activity Table S1 . Cont.
All experiments were conducted in three independent biological replicates performed in triplicate except for indicated miRNAs (**). These numbers are averages of two biological replicates performed in triplicate. Shaded rows indicate a P value < 0.01. 
AGAAACCTGGAAAGCCCCAACGCTGTGTCTCATGCTGTATACTTAAGAGGAGAAGAAAAAGTCCTATATTTGTG
Underlined boldfaced triplets signify nucleotides that are mutated compared to WT sequences.
